Merck KGaA to keep OTC
This article was originally published in The Tan Sheet
Executive Summary
The German firm maintains a positive outlook for its consumer health business and says it does not plan to sell - contrary to analysts' suggestion Sanofi-Aventis could buy it (1"The Tan Sheet," Jan. 12, 2009, p. 14). "If some braver companies are coming in, yes, that will increase the competition - the consumer will have more choice - but they cannot overtake our brands in two years," pharmaceutical head Elmar Schnee said during the firm's earnings call Feb. 18. Fiscal 2008 OTC revenues grew 5.2 percent to 442 million euros ($599.3 million under same-day conversion rates), and rose 3.7 percent to $144.7 million in the fourth quarter. The U.K.'s depreciating currency value hit the firm's sales
You may also be interested in...
Merck KGaA Consumer Business Could Flourish In The Right Hands – Analysts
Merck KGaA's weak consumer health business could be an acquisition target for a larger, more geographically diverse and innovative firm, such as Sanofi-Aventis, according to an analysts' report
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.